Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Phase IV Study of Rebif in CIS and RMS Patients Using RebiSmart in Romania
2014-001290-14Phase 4Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of interferon beta-1a in clinically isolated syndrome (CIS) and multiple sclerosis (MS) (2 cohorts), sponsored by Merck & Co. Primary endpoints: Relapse-free proportion at 12 months in RMS and Time to first relapse in CIS. Started Mar 2017; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
clinically isolated syndrome (CIS)multiple sclerosis (MS)
Beyond the preview
Go deeper on 2014-001290-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001290-14.